Medicinal Genomics uses its unmatched knowledge of the cannabis genome, P. cubensis genome, and the microbes that impact both organisms to create a variety of genomic services that provide valuable insights and actionable data.
Genotype plants, identify novel variants, and protect IP using the most advanced genomic tools on the market.
Map all 40+ million bases of the P. cubensis genome to the most complete and comprehensive reference genome, delivered on Psilocydia.net.
Identify which microbial species triggered a Total Yeast and Mold, Total Aerobic Count, or Bile Tolerant Gram Negative failure.
The Medicinal Genomics team has published extensively on the topics related to sequencing cannabis, hemp, mushrooms, and the microbes that affect them.
K McKernan, J Spangler, Y Helbert, RC Lynch, A Devitt-Lee, L Zhang, …F1000Research 5Read More >
K McKernan, J Spangler, L Zhang, V Tadigotla, Y Helbert, T Foss, D Smith F1000Research 4
KJ McKernan, Y Helbert, V Tadigotla, S McLaughlin, J Spangler, L Zhang, …BioRxiv, 028654Read More >
MGC CSO Kevin McKeran describes how his team constructed a chromosome-scale, annotated reference genome for Psilocybe cubensis and used it sequence and map an additional 81 Psilocybe genomes. He also debuta a new open source, blockchain-integrated genome browser called Psilocydia.
Our genetics-based cannabis testing and breeding technologies can help growers, dispensaries and labs grow cleaner, faster and healthier in every way. Because you’re not just delivering a product. You’re building a business. And a reputation.